

Myelofibrosis

[View the current Myelofibrosis InDepth page on BioPortfolio.com](#) ([PDF](#))

(<http://www.bioportfolio.com/indepth/Myelofibrosis.html>) - Regularly Updated.

Myelofibrosis with myeloid metaplasia, also known as agnogenic myeloid metaplasia, chronic idiopathic myelofibrosis, and primary myelofibrosis, was first described in 1879 and is currently classified as a myeloproliferative disease caused by the growth and proliferation of an abnormal bone marrow stem cell, resulting in the replacement of the bone marrow with fibrous connective tissue. An eponym for the disease is Heuck-Assmann disease, or Assmann's Disease. ([From the Wikipedia article Myelofibrosis](#).)

Recent Publications on Myelofibrosis:



- [Absence of Myelofibrosis in Dogs with Myelosuppression Induced by Ehrlichia canis Infection.](#)
*Bone marrow (BM) pathology was assessed in 10 dogs with Ehrlichia...*13th November, 2009
Companion Animal Clinic, Faculty of Veterinary Medicine, Aristotle- J Comp Pathol. 2009 Nov 9. ([DOI Direct Link](#))
- [International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis.](#)
*Among 200 patients with primary myelofibrosis, karyotype at diagnosis was...*11th November, 2009
Division of Hematology, Mayo Clinic, Rochester, MN, United States;- Blood. 2009 Nov 9. ([DOI Direct Link](#))
- [Wiped out.](#)
*Constitutive activation of the EPO/JAK2 signaling cascade has recently...*11th November, 2009
Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, USA.- Am J Med. 2009 Nov;122(11):1004-6. ([DOI Direct Link](#))
- [Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival.](#)
*Abstract Objectives: The current study was designed to identify...*10th November, 2009
Division of Hematology, Mayo Clinic, Rochester, MN, USA.- Eur J Haematol. 2009 Nov 6. ([DOI Direct Link](#))
- [Second Allogeneic Stem Cell Transplantation in Myeloid Malignancies.](#)
*For patients with myeloid malignancies who relapse after allogeneic stem...*6th November, 2009
Clinic for Stem Cell Transplantation, University Cancer Center Hamburg,- Acta Haematol. 2009 Oct 29;122(4):185-192. ([DOI Direct Link](#))
- [Combined Inhibition of Janus Kinase 1/2 for the Treatment of JAK2V617F-Driven Neoplasms: Selective Effects on Mutant Cells and Improvements in Measures of Disease Severity.](#)
*PURPOSE: Deregulation of the Janus kinase-signal transducers and...*6th November, 2009
Authors' Affiliations: Departments of Applied Technology, Preclinical- Clin Cancer Res. 2009 Nov 3. ([DOI Direct Link](#))
- [Outcome of transplantation for myelofibrosis.](#)

- Myelofibrosis is a myeloproliferative disorder incurable with conventional...* 3rd November, 2009
 Massachusetts General Hospital, Boston, Massachusetts, USA.- Biol Blood Marrow Transplant. 2009
 Oct 29. ([DOI Direct Link](#))
- [JAK2 V617F Mutation Detection: Laboratory Comparison of Two Kits Using RFLP and qPCR.](#)
Aim: The JAK2 V617F mutation has been implicated in a variety of diseases... 3rd November, 2009
 1 Department of Pathology & Laboratory Medicine, American University of- Genet Test Mol
 Biomarkers. 2009 Oct 30. ([DOI Direct Link](#))
 - [\[Patient with primary pyelofibrosis--extramedullary hematopoiesis in the pelvicalyceal system and ureters\]](#)
Aim: The JAK2 V617F mutation has been implicated in a variety of diseases... 3rd November, 2009
 - Ultraschall Med. 2009 Aug;30(4):323-6.
 - [TPO-mimetics and myelofibrosis? A reticulin question!](#)
Aim: The JAK2 V617F mutation has been implicated in a variety of diseases... 31st October, 2009
 University of Pennsylvania, USA.- Blood. 2009 Oct 29;114(18):3722-3. ([DOI Direct Link](#))
 - [Bone marrow findings at diagnosis in patients with multisystem Langerhans' cell histiocytosis.](#)
Abstract Objectives: This study was designed to describe the bone marrow... 30th October, 2009
 1 Hospital Nacional de Pediatria Dr Prof. J.P Garrahan.- Pediatr Dev Pathol. 2009 Oct 19. ([DOI Direct Link](#))
 - [Primary myelofibrosis relapsed with duodenal myeloid sarcoma after allogeneic stem cell transplantation.](#)
Abstract Objectives: This study was designed to describe the bone marrow... 29th October, 2009
 - Leuk Lymphoma. 2009 Nov;50(11):1879-81.
 - [\[Molecular mechanisms of myeloproliferative diseases and myelodysplastic syndromes\]](#)
Little was known about the mechanisms for myeloproliferative diseases... 29th October, 2009
 Department of Hematology and Oncology, Research Institute for Radiation- Nippon Rinsho. 2009
 Oct;67(10):1901-5.
 - [\[Classification of myeloid leukemias\]](#)
Myeloid leukemia in this series corresponds to the myeloid neoplasms of... 29th October, 2009
 Hematoimmunology, School of Health Science, Faculty of Medicine,- Nippon Rinsho. 2009
 Oct;67(10):1853-62.
 - [2-Aminopyrazolo\[1,5-a\]pyrimidines as potent and selective inhibitors of JAK2.](#)
Constitutive activation of the EPO/JAK2 signaling cascade has recently... 28th October, 2009
 Vertex Pharmaceuticals Inc, Cambridge, MA 02139-4242, United States.- Bioorg Med Chem Lett. 2009
 Dec 1;19(23):6529-33. Epub 2009 Oct 24. ([DOI Direct Link](#))

BioNews Results for Myelofibrosis

- [Incyte Reports Third Quarter 2009 Financial Results and Provides Update on Drug Development Programs](#)
NewsBlaze: Nov 5 2009 6:08PM Matching: myelofibrosis
- [Incyte Reports Third Quarter 2009 Financial Results and Provides Update on Drug Development Programs](#)
Genetic Engineering News: Nov 5 2009 1:37PM Matching: myelofibrosis
- [Incyte Reports Third Quarter 2009 Financial Results and Provides](#)
Business Wire via MSN Money: Nov 5 2009 12:41PM Matching: myelofibrosis
- [Incyte Reports Third Quarter 2009 Financial Results and Provides Update on Drug Development Programs](#)
Street Insider: Nov 5 2009 12:28PM Matching: myelofibrosis
- [Incyte Reports Third Quarter 2009 Financial Results and Provides Update on Drug Development Programs](#)

- Business Wire: Nov 5 2009 12:22PM Matching: myelofibrosis*
- [TargeGen Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patient](#)
PR Newswire: Oct 28 2009 12:23PM Matching: myelofibrosis
 - [TargeGen Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patient](#)
Pharma Live: Oct 25 2009 1:47AM Matching: myelofibrosis
 - [TargeGen, Inc. Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis P](#)
BioSpace: Oct 23 2009 5:52PM Matching: myelofibrosis
 - [Medical News: TargeGen Announces Successful Completion Of Clinical Trial Of JAK2 Inhibitor TG101348 In Myelofibrosis Patients](#)
Medical News Today: Oct 23 2009 1:12PM Matching: myelofibrosis
 - [TargeGen Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patient](#)
KOTA Territory News: Oct 23 2009 11:57AM Matching: myelofibrosis
 - [First Myelofibrosis Treatment Trial Ends](#)
Pharmaceutical Technology: Oct 23 2009 10:31AM Matching: myelofibrosis
 - [TargeGen Announces Successful Completion Of Clinical Trial Of JAK2 Inhibitor TG101348 In Myelofibrosis Patient](#)
Medical News Today: Oct 23 2009 9:55AM Matching: myelofibrosis
 - [TargeGen Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients](#)
SmartBrief: Oct 22 2009 11:50PM Matching: myelofibrosis
 - [TargeGen Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patient](#)
Genetic Engineering News: Oct 22 2009 9:12PM Matching: myelofibrosis
 - [Myelofibrosis Prognosis: Researchers from Miyazaki University describe findings in myelofibrosis prognosis](#)
NewsRX: Oct 6 2009 7:52AM Matching: myelofibrosis

Myelofibrosis Clinical Trials:



- [A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia \(CMML\)](#)

Myelofibrosis Patents:



- 7442805- [Substituted sulfonamide-indoles](#)
- 7507414- [Albumin fusion proteins](#)
- 7507860- [Androgen modulators](#)
- 7514229- [Methods for diagnosing and evaluating treatment of blood disorders](#)
- 7514440- [Fused pyrrolocarbazoles](#)
- 7517856- [Bioconjugates comprising sulfated polysaccharides and their uses](#)
- 7521424- [Albumin fusion proteins](#)
- 7521446- [Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith](#)
- 7524937- [WSX receptor agonist antibodies](#)
- 7528142- [Aminopyrimidines useful as kinase inhibitors](#)
- 7528143- [Bi-aryl meta-pyrimidine inhibitors of kinases](#)
- 7507413- [Albumin fusion proteins](#)
- 7501415- [Selective inhibitors of ERK protein kinase and uses thereof](#)
- 7498299- [Procollagen \(III\) propeptides and related substances for treating fibrotic diseases](#)
- 7446201- [Substituted heteroaryl benzofuran acids](#)
- 7459478- [Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 \(PAI-1\)](#)
- 7459531- [50 Human secreted proteins](#)
- 7465548- [Methods of screening for potential therapeutics for diseases associated with G-protein coupled receptor HM74a](#)
- 7470709- [Benzimidazole quinolinones and uses thereof](#)
- 7470807- [Substituted arylalkanoic acid derivatives and use thereof](#)
- 7473711- [Androgen modulators](#)
- 7482013- [Albumin fusion proteins](#)
- 7491550- [Diagnostics and therapeutics for diseases associated with Neuromedin U2 receptor \(NMU2\)](#)
- 7491732- [Compositions and methods for inhibition of the JAK pathway](#)
- 7534894- [Biphenyloxy-acids](#)
- 7541149- [Monoclonal antibody and assay for detecting PIINP](#)
- 7591993- [Polyvinyl alcohol microspheres, and injectable solutions of the same](#)
- 7592010- [Albumin fusion proteins](#)
- 7595378- [Human monoclonal antibodies to epidermal growth factor receptor \(EGFR\)](#)
- 7597884- [Hyperglycosylated polypeptide variants and methods of use](#)
- 7598257- [Heteroaryl substituted pyrrolo\[2,3-b\]pyridines and pyrrolo\[2,3-b\]pyrimidines as janus kinase inhibitors](#)
- 7598268- [Quinolinone derivatives](#)
- 7604990- [Methods of regulating differentiation in stem cells](#)
- 7605172- [Thiazolo-naphthyl acids](#)
- 7608704- [Secreted proteins](#)
- 7612094- [Tri-substituted heteroaryls and methods of making and using the same](#)
- 7582773- [Substituted phenyl indoles](#)
- 7576186- [Compositions and methods for stem cell delivery](#)
- 7576128- [Androgen receptor modulators](#)
- 7547437- [Method of treating fibrosis](#)
- 7547766- [Anti-tango294 antibodies and uses thereof](#)
- 7547804- [Compounds, compositions, and methods employing same](#)
- 7553494- [WT1 fusion proteins](#)
- 7553854- [6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling](#)
- 7553866- [Thiolactones](#)
- 7563810- [Methods of using 3-\(4-amino-1-oxo-1,3-dihydroisoindol-2-yl\)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases](#)
- 7566791- [Substituted 3-carbonyl-1h-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 \(PAI-1\)](#)

- 7569384- [Albumin fusion proteins](#)
- 7569385- [Multipotent amniotic fetal stem cells](#)
- 7615552- [Fused heterocyclic compounds](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

